Table 3 Impact of COVID-19 on NMD
From: A multicenter cross-sectional French study of the impact of COVID-19 on neuromuscular diseases
Without effect (n = 48) No. (%) | Aggravating factor (n = 26) No. (%) | Death (n = 9) No. (%) | p value | |
|---|---|---|---|---|
Type of disease | 0.716 | |||
Myopathy | 17 (63) | 8 (29.6) | 2 (7.4) | |
Neuropathy | 15 (65.2) | 6 (26.1) | 2 (8.7) | |
Myasthenia | 16 (48.5) | 12 (36.4) | 5(15.2) | |
Origin of the disease | 0.322 | |||
Acquired | 23 (53.5) | 13 (30.2) | 7 (16.3) | |
Genetic | 24 (61.5) | 13 (33.3) | 2 (5.1) | |
Severity of neuromuscular diseaseƗ | 0.170 | |||
Low | 21 (70.0) | 7 (23.3) | 2 (6.7) | |
Moderate | 19 (54.3) | 13 (37.1) | 3 (8.6) | |
High | 6 (37.5) | 6 (37.5) | 4 (25.0) | |
Mobility | 0.110 | |||
Walk | 35 (61.4) | 20 (35.1) | 2 (3.5) | |
Walk with help | 7 (58.3) | 3 (25.0) | 2 (16.7) | |
Wheelchair | 6 (50.0) | 3 (25.0) | 3 (25.0) | |
Gender | 0.079 | |||
Men | 15 (44.1) | 13 (38.2) | 6 (17.6) | |
Women | 33 (67.3) | 13 (26.5) | 3 (6.1) | |
Age > 65 yrs old | 9 (47.4) | 8 (42.1) | 2 (10.5) | 0.553 |
Respiratory failure | 13 (48.1) | 10 (37.0) | 4 (14.8) | 0.233 |
Heart failure | 12 (75.0) | 3 (18.8) | 1 (6.2) | 0.401 |
Obesity | 0 | 7 (87.5) | 1 (12.5) | 0.001* |
Hypertension | 4 (36.4) | 4 (36.4) | 3 (27.3) | 0.097 |
Diabetes | 2 (20.0) | 3 (30.0) | 5 (50.0) | < 0.001* |
Corticosteroids‡,§ | 9 (69.2) | 2 (15.4) | 2 (15.4) | 0.394 |
Immunosuppressants other than corticosteroids‡,§ | 9 (60.0) | 5 (33.3) | 1 (6.7) | 0.565 |